Literature DB >> 7786636

Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects.

A Chines1, A Boniface, W McAlister, M Whyte.   

Abstract

In 1991, we reported that hypercalciuria is a common finding in our pediatric patient population with osteogenesis imperfecta (OI) (17 of 47 = 36%). Here, we prospectively screened 12 of these hypercalciuric children, on average 4 years subsequent to the discovery of elevated urine calcium levels, for adverse effects on renal function. Despite an ad libitum decrease since initial investigation of about 30% in their previously normal dietary calcium intake (adjusted for body weight), 8 of the 12 patients remained hypercalciuric (urine calcium/creatinine > 0.62 mmol/mmol). We found, once again, that urinary calcium levels significantly correlated with the severity of the skeletal disease as assessed by z-score for height (r = -0.75, p = 0.005). Evaluation of kidney function, however, revealed: (i) normal routine urinalysis in all but 1 subject who had transient microscopic hematuria; (ii) unremarkable concentrating ability determined by fasting urine osmolality; (iii) normal creatinine clearance, and (iv) unremarkable ultrasonography to measure renal size and to screen for nephrocalcinosis or nephrolithiasis. Although no significant renal compromise was detected with these studies in our hypercalciuric pediatric OI patients, investigation of affected adults, especially those severely affected, will be important to assess whether this is a long-term problem and if adverse effects on the kidneys do develop.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786636     DOI: 10.1016/8756-3282(94)00046-8

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  Extraperitoneal laparoscopy-assisted percutaneous nephrolithotomy in a patient with osteogenesis imperfecta.

Authors:  Seref Basal; Yasar Ozgok; Lutfi Tahmaz; Abdulkadir Atim; Murat Zor; Serkan Bilgic; Okan Istanbulluoglu
Journal:  Urol Res       Date:  2010-03-14

Review 2.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

3.  Generalized connective tissue disease in Crtap-/- mouse.

Authors:  Dustin Baldridge; Jennifer Lennington; MaryAnn Weis; Erica P Homan; Ming-Ming Jiang; Elda Munivez; Douglas R Keene; William R Hogue; Shawna Pyott; Peter H Byers; Deborah Krakow; Daniel H Cohn; David R Eyre; Brendan Lee; Roy Morello
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

Review 4.  Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta.

Authors:  Joan C Marini; Wayne A Cabral; Aileen M Barnes
Journal:  Cell Tissue Res       Date:  2009-10-28       Impact factor: 5.249

5.  Osteogenesis Imperfecta with Celiac Disease and Type II Diabetes Mellitus Associated: Improvement with a Gluten-Free Diet.

Authors:  Luis Rodrigo; Isabel Pérez-Martinez
Journal:  Case Rep Med       Date:  2012-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.